ArticleAlzheimer's research & therapy2022
Detection of plasma Aβ seeding activity by a newly developed analyzer for diagnosis of Alzheimer's disease.
Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on Body Fluid, Gene and Neuroimaging Biomarkers for Early Diagnosis of Alzheimer's Disease
Detection of Alzheimer's Disease (AD)-Related Seeds as Biomarkers for Accurate Diagnosis of AD（AD-seeds-detector）
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.Neurodegenerative disease management · 2026Review
- Amyloid-β Seeds in Alzheimer's Disease: Research Challenges and Implications.Journal of neurochemistry · 2025Review
- The China Alzheimer Report 2025.General psychiatry · 2025Review
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic value of plasma β-amyloid (Aβ) seeding activity measured using a newly developed instrument to distinguish Alzheimer's disease (AD) from other forms of dementia.
methodsSeventy-nine AD patients, 64 non-AD dementia (NADD) patients, and 75 cognitively normal (NC) subjects were recruited in the study. To measure the levels of Aβ seeding activity in the plasma samples, we have developed an AD-seeds protein analyzer. We used receiver operating characteristic (ROC) curves to quantify the ability of plasma Aβ seeding activity to distinguish between AD and NADD or NC individuals. Spearman's correlation was used to examine the associations between plasma Aβ seeding activity and global cognitive function or conventional AD biomarkers.
resultsThe Aβ seeding activities were 0.83 (0.58-1.16) A.U. in AD, 0.42 (0.04-0.74) A.U. in NADD and 0.42 (0.09-0.69) A.U. in NC, respectively. The Aβ seeding activity was able to identify AD patients and distinguish them from NC or NADD with high accuracy (AUC = 0.85-0.86). In addition, the plasma Aβ seeding activity showed a strong correlation with cognitive performance (mini-mental state examination, r = - 0.188; Montreal cognitive assessment, r = - 0.189; clinical dementia rating, r = 0.205) and conventional biomarkers (cerebrospinal fluid [CSF] Aβ42/40, r = -0.227; CSF T-tau/Aβ42, r = 0.239; CSF P-tau/Aβ42, r = 0.259).
conclusionOur results confirmed that plasma Aβ seeding activity is an antibody-free and low-cost biomarker for the diagnosis of AD.
trial registrationTrial registration number NCT04850053.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.